Publications by authors named "Yuliya N Pirogova"
A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC). These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancer-related genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones.
View Article and Find Full Text PDFLung cancer is currently the second leading cause of cancer death worldwide. In recent years, checkpoint inhibitor immunotherapy (ICI) has emerged as a new treatment. A better understanding of the tumor microenvironment (TMJ) or the immune system surrounding the tumor is needed.
View Article and Find Full Text PDFArticle Synopsis
- Research indicates that growth factors play a significant role in lung cancer angiogenesis, which helps tumors grow and spread by affecting the immune response.
- New treatment strategies focus on developing anti-angiogenic compounds that block the activity of these growth factors, particularly EGF and VEGF, to hinder lung cancer progression.
- While the initial results of these therapies are promising, there is a heightened risk of toxicity, necessitating personalized follow-up care for patients undergoing treatment.